Formulation And Characterization Of Plga Nanoparticles Loaded With Doxorubicin For Breast Cancer

Abstract

Doxorubicin (DOX) is a potent chemotherapeutic agent widely used in breast cancer treatment, but its clinical application is limited due to systemic toxicity and multidrug resistance. To overcome these challenges, this study focuses on the formulation and characterization of poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) loaded with DOX for targeted breast cancer therapy. DOX-loaded PLGA nanoparticles were synthesized using optimized techniques such as single emulsion and layer-by-layer (LbL) self-assembly with biocompatible polymers like chitosan and dextran sulfate to enhance stability, drug encapsulation, and controlled release. The nanoparticles exhibited spherical morphology with uniform size distribution around 170–200 nm, a favorable zeta potential indicating stability, and high drug loading efficiency. In vitro studies demonstrated controlled and pH-sensitive release profiles with significantly reduced initial burst release, improving drug bioavailability and minimizing toxicity. Cellular uptake and cytotoxicity assays on DOX-resistant and sensitive breast cancer cell lines showed enhanced uptake, increased apoptosis, and superior cytotoxic effects of the nanoparticle formulations compared to free DOX. In vivo studies confirmed improved tumor growth inhibition with lower systemic side effects. These findings highlight the potential of DOX-loaded PLGA nanoparticles as an effective nanomedicine platform for breast cancer treatment, addressing toxicity and resistance issues while enhancing therapeutic efficacy  (2017).